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Cytokines are small protein molecules which play a key
role in viral clearance. Interferon-alpha (IFN) is a proin-
flammatory cytokine that is used to treat hepatitis C.
However, the use of IFN can result in the development of
neuropsychiatric side effects and sickness behavior, such
as depression, irritability and fatigue. IFN-induced depres-
sion occurs in approximately 20-30% of patients with
HCV, yet the mechanisms and risk factors associated with
this complication of its use are not well understood.
In patients chronically infected with the hepatitis C virus
(HCV) and/or the human immunodeficiency virus (HIV)
the there is a high prevalence of substance use and psychi-
atric disorders. Although, IFN-based therapies are the cur-
rent treatment for patients with HCV, many patients with
psychiatric or substance use disorders do not receive these
therapies. Health care providers can be reluctant to treat
these patients because of non-compliance concerns and
neuropsychiatric side effects of IFN therapy, particularly
depression. Increasingly, basic scientists, hepatologists,
mental health and other health care providers have recog-
nized the need for improved treatment strategies for HCV,
one that addresses the co-entwined epidemics of chronic
infection, substance abuse and psychiatric illness.
In general, IFN-induced depression worsens with increas-
ing dose and duration of therapy. However, there are no
established premorbid risk factors (e.g., the patient's past
history, pre-therapy physical or psychiatric condition)
that reliably predict the development of IFN-induced
depression. Clinical experience and neurochemical and
genetic research suggest underlying causes for the neu-
ropsychiatric side effects induced by IFN and also suggest
approaches to ameliorating those side effects. Antiviral
therapy for patients with HCV is best provided through
integrating medical, psychiatric, and substance abuse care.
Establishing care pathways, group education, and stand-
ardized screenings greatly enhances this approach.
Although there are gaps in our understanding of the opti-
mal HCV treatment in patients with comorbid psychiatric
and substance use disorders, in the future we must con-
tinue to expand our definition of HCV care to include
these patients so that new management strategies and
novel interventions can be developed and thus improve
treatment outcomes for this underserved patient popula-
tion.
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